Copyright
©The Author(s) 2015.
World J Hepatol. Feb 27, 2015; 7(2): 213-225
Published online Feb 27, 2015. doi: 10.4254/wjh.v7.i2.213
Published online Feb 27, 2015. doi: 10.4254/wjh.v7.i2.213
Figure 1 Management of hepatitis C virus in patients with renal disease and kidney transplantation.
Empiric dose changes should be done in conjunction with therapeutic drug monitoring. BOC: Boceprevir; TVR: Telaprevir; SMV: Simeprevir; SFV: Sofosbuvir; CYP3A4: Cytochrome P450 3A4; mTOR: Mammalian target of rapamycin; MMF: Mycophenolate mofetil.
- Citation: Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D. Management of patients with hepatitis C infection and renal disease. World J Hepatol 2015; 7(2): 213-225
- URL: https://www.wjgnet.com/1948-5182/full/v7/i2/213.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i2.213